AbbVie reports 'positive' data from Phase 2/3 SELECT-AXIS 1 trial
AbbVie announced positive data from the Phase 2/3 SELECT-AXIS 1 trial in which twice as many adult patients with active ankylosing spondylitis treated with RINVOQ achieved the primary endpoint of Assessment of SpondyloArthritis International Society 40 response at week 14 versus placebo. SELECT-AXIS 1 is the first trial to evaluate the efficacy and safety of RINVOQ in adult patients with active AS who are naive to biologic disease-modifying antirheumatic drugs and had inadequate response or intolerance to nonsteroidal anti-inflammatory drugs. Full results were presented today at the 2019 American College of Rheumatology/Association for Rheumatology Professionals Annual Meeting in Atlanta and have been published concurrently in The Lancet. RINVOQ, a JAK inhibitor discovered and developed by AbbVie, is being studied as a once-daily therapy in AS and multiple immune-mediated inflammatory diseases. "Ankylosing spondylitis is a chronic, progressive, inflammatory disease that causes pain and stiffness, primarily in the spine, starting in early adulthood," said Desiree van der Heijde, Professor, Leiden University Medical Center, the Netherlands. "Apart from biologics, there are limited options available for patients who have an inadequate response or contraindication to NSAIDs. The results of this study highlight the potential of RINVOQ as an additional treatment option for patients living with ankylosing spondylitis."